Long-Term Efficacy Observation of Recombinant Bone Xenograft in Treatment of Femoral Non-Infected Nonunion
YU Zhong-ying,YUAN Zhi,ZHANG Wei,LI Yan,CHEN Zhao,MA Zhi-jun,YU Yuan
DOI: https://doi.org/10.13241/j.cnki.pmb.2012.07.030
2012-01-01
Abstract:Objective: To evaluate long-term efficacy of recombinant bone xenograft in treatment of femoral non-infected nonunion.Methods: 37 patients suffered with femoral non-infected nonunion since 2000 was analyzed retrospectively,which included 26 males and 11 females,with the mean age of 31.6 years(ranged from 4 to 70 years).The nonunion site: the proximal femur in 4 cases,the middle 30 cases,3 cases of distal.There were 9 hypertrophic,6 malnourished,22 atrophic.24 cases with plate,11 cases with intramedullary nailing and 2 cases with external fixation.Results: The average follow-up time of these cases was 90.2 months,from 51 months to 131 months.94.6% of these patients healed with only one operation.By the Harris scale,of the 4case of proximal femoral nonunion,the hip functions were rate as excellent in 3,good in 4 and no fair,with an excellent to good rate of 100%.By the American Knee Society Score(KSS),of the 3cases of distal femoral nonunion,the knee function was rated as excellent in 1,good in 1 and fair in 1,with an excellent to good rate of 66.7%.By the sanders Kss systems,of the 30 cases of femoral shaft nonunion,the hip and knee functions were rated as excellent in 21,good in 8 and fair in 1,with an excellent to good rate of 96.7%.The total excellent to good rate was 94.6%.No one has immune rejection in this long-term observation.Conclusion: RBX for the treatment of femoral non-infected nonunion has many advantages,such as sufficient materia,high rate of fracture healing,a nice biological compatibility,it can be used in the clinic instead of autologous bone.